Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TAL-MRD: Talquetamab Added to Lenalidomide Maintenance for MRD-Positive Multiple Myeloma
KCT0012388Phase 2Not yet recruiting
- Sponsor
- Janssen Pharmaceutical
- Start
- Sep 2026
- Modality
- T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, single-arm trial of talquetamab in multiple myeloma (MM), sponsored by Janssen Pharmaceutical. Planned start Sep 2026; status: not yet recruiting.
02
Drugs
talquetamab
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on KCT0012388.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on KCT0012388.